Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2019 Oct;106(4):726-733.
doi: 10.1002/cpt.1477. Epub 2019 Jul 5.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

Zeruesenay Desta  1 , Roseann S Gammal  2   3 , Li Gong  4 , Michelle Whirl-Carrillo  4 , Aditya H Gaur  5 , Chonlaphat Sukasem  6   7 , Jennifer Hockings  8 , Alan Myers  9 , Marelize Swart  1 , Rachel F Tyndale  10 , Collen Masimirembwa  11 , Otito F Iwuchukwu  12 , Sanika Chirwa  13 , Jeffrey Lennox  14 , Andrea Gaedigk  15 , Teri E Klein  4 , David W Haas  13   16
Affiliations
Practice Guideline

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

Zeruesenay Desta et al. Clin Pharmacol Ther. 2019 Oct.

Abstract

The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

As an Associate Editor for Clinical Pharmacology & Therapeutics, Rachel Tyndale was not involved in the review or decision process for this paper. All other authors declared no competing interests for this work.

Figures

Figure 1
Figure 1
Schematic representation of efavirenz metabolism and mechanism of action against HIV (12, 14) An interactive version of the pathway is available at: https://www.pharmgkb.org/pathway/PA166123135). Image reproduced and is licensed under CC BY-SA 4.0 from PharmGKB.
See this image and copyright information in PMC

References

    1. CPIC. CPIC Guideline for Efavirenz based on CYP2B6 genotype <https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp...> (2018).
    1. Hofmann MH et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325, 284–92 (2008). - PubMed
    1. Zanger UM & Klein K Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 4, 24 (2013). - PMC - PubMed
    1. Holzinger ER et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics 22, 858–67 (2012). - PMC - PubMed
    1. Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Manosuthi S & Sungkanuparph S CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1. Antimicrob Agents Chemother 58, 2268–73 (2014). - PMC - PubMed

Publication types